Criminal probe into Valeant's former execs sends share price plummeting

1 November 2016

More than 12% was wiped off the share price of Valeant Pharmaceuticals International (TRX: VRX) after a report that former bosses at the Canadian drugmaker were the subject of a criminal investigation.

US prosecutors are focusing on former chief executive Michael Pearson and ex-chief financial officer Howard Schiller as they build a case against the firm which could lead to accounting fraud charges being brought within weeks, according to Bloomberg.

The news service reports that sources suggest the investigation centers on the company’s ties to Philidor Rx Services, a specialty pharma company that Valeant secretly controlled.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK